Frequently Asked Questions About Sildenafil Hexal

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Author information

The role of botulinum toxin a in the treatment of Raynaud phenomenon. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. [DOI] [PMC free article] [PubMed] [Google Scholar] 68.Nagaraja V, Spino C, Bush E, et al. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. [DOI] [PMC free article] [PubMed] [Google Scholar] 69.R Lm D, Goundappa B, Medsger T, et al. [DOI] [PMC free article] [PubMed] [Google Scholar] Changes in causes of death in systemic sclerosis, 19722002. [DOI] [PMC free article] [PubMed] [Google Scholar] 72.Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. [DOI] [PMC free article] [PubMed] [Google Scholar] 73.Fisher MR, Mathai SC, Champion HC, et al.

Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. New insights into the recognition, classification and management of systemic sclerosis-associated pulmonary hypertension. Association between initial oral therapy and outcomes in systemic sclerosis-related pulmonary arterial hypertension. March;68(3):740–748.

TOURNES 100mg Contraindications TOURNES 100mg

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Infusion of iloprost, a prostacyclin analogue, for treatment of sildenafil pfizer 100g Raynaud’s phenomenon in systemic sclerosis. Iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion.

Cite this chapter

[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Shah AA, Schiopu E, Chatterjee S, et al. The recurrence of digital ulcers in patients with systemic sclerosis after discontinuation of oral treprostinil. Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1). [DOI] [PMC free article] [PubMed] [Google Scholar] 61.Gaillard-Bigot F, Roustit M, Blaise S, et al. Treprostinil iontophoresis improves digital blood flow during local cooling in systemic sclerosis. [DOI] [PMC free article] [PubMed] [Google Scholar] 76.Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension.

3. Conclusion

[DOI] [PubMed] [Google Scholar] 35.Volkmann ER, Tashkin DP, Kuwana M, et al. Progression of Interstitial Lung Disease in Systemic Sclerosis: the Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. December;71(12):2059–2067. [DOI] [PMC free article] [PubMed] [Google Scholar] 36.Fischer A, Strek ME, Cottin V, et al. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland connective tissue disease-associated interstitial lung disease summit: a multidisciplinary approach to address challenges and opportunities.

Authors and Affiliations

February;71(2):182–195. [DOI] [PubMed] [Google Scholar] 37.Goldin JG, Kim GHJ, Tseng CH, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the scleroderma lung study II. [DOI] [PMC free article] [PubMed] [Google Scholar] 38.Khanna D, Yan X, Tashkin DP, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. [DOI] [PMC free article] [PubMed] [Google Scholar]; • This open-label trial was one of the first studies to demonstrate the hemodynamic benefits from upfront combination vasodilatory therapy in SSc-PAH.

A randomized double blind placebo controlled trial to compare the efficacy of initial combination therapy vs monotherapy for pulmonary arterial hypertension in systemic sclerosis. Criteria for diagnosis of exercise pulmonary hypertension. Exercise pulmonary sildenafil gel haemo-dynamics predict outcome in patients with systemic sclerosis.

Abnormal pulmonary artery systolic pressure response after exercise in systemic sclerosis patients: A PRISMA-compliant meta-analysis.

• Men with anatomical penile deformities should consult a doctor first.
• Keep a record of any side effects experienced.
• Medical review is recommended if no improvement occurs.
• Use with caution if you have heart disease.
• Be aware of potential drug interactions.

[DOI] [PMC free article] [PubMed] [Google Scholar] 81.Saggar R, Khanna D, Shapiro S, et al. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. [DOI] [PMC free article] [PubMed] [Google Scholar] 83.Gaine S, Chin K, Coghlan G, et al.

Frequently Asked Questions

Effects of 1-year sildenafil 50mg tablet treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. [DOI] [PMC free article] [PubMed] [Google Scholar] 40.Volkmann ER, Tashkin DP, Sim M, et al. Cyclophosphamide for systemic sclerosis-related interstitial lung disease: a comparison of scleroderma lung study I and II. [DOI] [PMC free article] [PubMed] [Google Scholar] 41.Volkmann ER, Tashkin D. Roth M, LeClair H, et al.

Download citation

Mycophenolate mofetil and cyclophosphamide improve health-related quality of life in patients with systemic sclerosis who participated in SLS II. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. [DOI] [PMC free article] [PubMed] [Google Scholar] 45.Saunders P, Tsipouri V, Keir GJ, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.

• Sildenafil 100mg Hexal is a PDE5 inhibitor medication.
• It’s effective for men with erectile dysfunction of various causes.
• Avoid taking it with fatty foods to improve absorption.
• Long-term safety depends on medical supervision.
• Report any worsening symptoms to your doctor.

[DOI] [PMC free article] [PubMed] [Google Scholar] 84.Catania MV, Sortino MA, Rampello L, et al.

Dosage of TOURNES 100mg

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. [DOI] [PMC free article] [PubMed] [Google Scholar] 47.Nihtyanova SI, Brough GM, Black CM, et al. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. On-demand sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study.

Areas covered:

Sep-Oct;35(Suppl 106(4)):151–158. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. Adenosine deaminase increases release of excitatory amino acids through a mechanism independent of adenosine depletion. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention.

Related Products

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopatho-logical study. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis.

Erektile Dysfunktion (ED)

Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Severe restrictive lung disease in systemic sclerosis. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. October;69(10):1809–1815. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial. Effectiveness of saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial.

Copyright information

Treprostinil hydrogel iontophoresis in systemic sclerosis-related digital skin ulcers: a safety study. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. [DOI] [PMC free article] [PubMed] [Google Scholar] 64.Khanna D, Denton CP, Merkel PA, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon. [DOI] [PMC free article] [PubMed] [Google Scholar] 89.Bharadwaj S, Tandon P, Gohel T, et al. Gastrointestinal manifestations, malnutrition, and role of enteral and parenteral nutrition in patients with scleroderma. Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel.